Potential clinical applications of siRNA technique: Benefits and limitations

European Journal of Clinical Investigation

Volumn 41, Issue 2, 2011, Pages 221-232

  Chen, Shao Hua ^a   Zhaori, Getu ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b English Edition   (China)

Author keywords

Cancer treatment; Clinical application; RNA interference; Small or short interfering RNA

Indexed keywords

DOXORUBICIN; GEMCITABINE; POLYETHYLENIMINE P 32; RADIOPHARMACEUTICAL AGENT; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER THERAPY; CARDIOTOXICITY; CORONARY ARTERY DISEASE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; HUMAN; IN VIVO STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESTENOSIS; REVIEW; RNA INTERFERENCE; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE SILENCING; HUMANS; NEOPLASMS; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 78651314500     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02400.x     Document Type: Review

References (56)

1. Hokaiwado N, Takeshita F, Banas A, Ochiya T. RNAi-based drug discovery and its application to therapeutics. IDrugs 2008;11:274-8.
2. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 2007;76:9-21.
3. DeVincenzo J, Lambkin-Williams R, Wilkinsonc T, Cehelskyd J, Nochurd S, Walshe E et al. A randomized, double-blind, placebo- controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010;107:8800-5.
4. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18:305-19.
5. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007;59:164-82.
6. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010;18:442-6.
7. Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV et al. Sirna-027 Study Investigators. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010;150:33-9.
8. Bonetta L. RNA-based therapeutics: ready for delivery? Cell 2009;136:581-4.
9. Kaufmann J, Ahrens K, Santel A. RNA interference for therapy in the vascular endothelium. Microvasc Res 2010;80:286-93.
10. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007;121:2307-16.
11. Ohri SS, Vashishta A, Proctor M, Fusek M, Vetvicka V. Depletion of procathepsin D gene expression by RNA interference: a potential therapeutic target for breast cancer. Cancer Biol Ther 2007;6:1081-7.
12. Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla ZM. Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther 2009;16:217-26.
13. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009;15:2657-65.
14. Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol 2009;34:1209-20.
15. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009;35:553-62.
16. Song X, Wang JB, Yin DL, Yang HY, Liu LX, Jiang HC. Down-regulation of lung resistance related protein by RNA interference targeting survivin induces the reversal of chemoresistances in hepatocellular carcinoma. Chin Med J (Engl) 2009;122:2636-42.
17. Chen T, Deng C. Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int Immunopharmacol 2008;8:1006-11.
18. Shen W, Wang CY, Wang XH, Fu ZX. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009;28:81.
19. Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q et al. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin (Shanghai) 2009;41:223-30.
20. Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 2008;32:1049-56.
21. Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. STAT3: a Target to Enhance Antitumor Immune Response. Curr Top Microbiol Immunol 2010; [Epub ahead of print].
22. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 2009;57:1458-67.
23. Regis G, Icardi L, Conti L, Chiarle R, Piva R, Giovarelli M et al. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia 2009;23:2102-8.
24. Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2007;2:59-71.
25. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 2008;129:107-16.
26. He XW, Yu X, Liu T, Yu SY, Chen DJ. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. Chin Med J (Engl) 2008;121:439-44.
27. Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH et al. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol 2007;31:1039-50.
28. Shi XH, Liang ZY, Ren XY, Liu TH. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 2009;16:227-36.
29. Meyer M, Dohmen C, Philipp A, Kiener D, Maiwald G, Scheu C et al. Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. Mol Pharm 2009;6:752-62.
30. Podesta JE, Al-Jamal KT, Herrero MA, Tian B, Ali-Boucetta H, Hegde V et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009;5:1176-85.
31. Zheng X, Vladau C, Zhang X, Suzuki M, Ichim TE, Zhang ZX et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009;113:2646-54.
32. Xia CF, Boado RJ, Pardridge WM. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm 2009;6:747-51.
33. Tummalapalli P, Gondi CS, Dinh DH, Gujrati M, Rao JS. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol 2007;31:5-17.
34. Ren X, Xu Y, Bao W, Fu H, Wu C, Zhao Y et al. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Cancer Lett 2009;281:134-43.
35. Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008;14:6432-9.
36. Kamlah F, Eul BG, Li S, Lang N, Marsh LM, Seeger W et al. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 2009;16:195-205.
37. Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 2008;272:148-59.
38. Tang H, Wang J, Bai F, Hong L, Liang J, Gao J et al. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem Cell Biol 2007;85:103-10.
39. Dai Y, Qiao L, Chan KW, Yang M, Ye J, Zhang R et al. Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer. Mol Cancer Ther 2009;8:2762-70.
40. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ et al. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 2008;27:7192-200.
41. Wang F, Chen L, Mao ZB, Shao JG, Tan C, Huang WD. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep 2008;20:135-9.
42. Iwaki K, Shibata K, Ohta M, Endo Y, Uchida H, Tominaga M et al. A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model. Int J Cancer 2008;122:658-63.
43. Singhal SS, Roth C, Leake K, Singhal J, Yadav S, Awasthi S. Regression of prostate cancer xenografts by RLIP76 depletion. Biochem Pharmacol 2009;77:1074-83.
44. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. Methods Mol Biol 2009;555:29-42.
45. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008;123:348-56.
46. Réjiba S, Bigand C, Parmentier C, Hajri A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 2009;11:637-50.
47. Moss LS, Starbuck MF, Mayer DK, Harwood EB, Glotzer J. Trastuzumab-induced cardiotoxicity. Oncol Nurs Forum 2009;36:676-85.
48. Sakamoto N, Tanabe Y, Yokota T, Satoh K, Sekine-Osajima Y, Nakagawa M et al. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. J Gastroenterol Hepatol 2008;23:1437-47.
49. Tan C, Xuan B, Hong J, Dai Z, Hao R, Li Z et al. RNA interference against hepatitis B virus with endoribonuclease-prepared siRNA despite of the target sequence variations. Virus Res 2007;126:172-8.
50. Alvarez R, Elbashir S, Borland T, Toudjarska I, Hadwiger P, John M et al. RNA interference-mediated silencing of the respiratory syncytial virusnucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009;53:3952-62.
51. Fechner H, Sipo I, Westermann D, Pinkert S, Wang X, Suckau L et al. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J Mol Med 2008;86:987-97.
52. Hlawaty H, San JuanA, Jacob MP, Vranckx R, Letourneur D, Feldman LJ. Local matrix metalloproteinase 2 gene knockdown in balloon-injured rabbit carotid arteries using nonviral-small interfering RNA transfection. J Gene Med 2009;11:92-9.
53. Hlawaty H, San Juan A, Jacob MP, Vranckx R, Letourneur D, Feldman LJ. Inhibition of MMP-2 gene expression with small interfering RNA in rabbit vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007;293:H3593-601.
54. Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler AA III. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol 2007;293:H1571-80.
55. Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 2009;236:97-108.
56. Merkel OM, Librizzi D, Pfestroff A, Schurrat T, Béhé M, Kissel T. In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. Bioconjug Chem 2009;20:174-82.